Redeye provides its initial take on BONESUPPORT’s Q4 report and expects a positive reaction of c.
Q-linea's partner Thermo Fisher is launching ASTar in Europe, and Q4 is the first quarter featuring ...
Redeye comments on the Q3-report from Embracer. Operational EBIT was almost exactly as we had estima...
Redeye states that the Q4 report was rock-solid with much higher profitability than we had estimated...
MOBA delivered a strong report, Sales were 18% ahead of our expectations while EBIT was 14% ahead.
Redeye will likely make slight estimate changes on the back of Artificial Solutions' year-end report...
Redeye’s expectation on Q4 results were only slightly higher than reported numbers.
Redeye’s preliminary estimate revisions suggest unchanged sales forecasts and lowered EBIT estimates...
Net sales was 8% above consensus (Infront) in Q4. Clean operating profit was very good in Q4 due to ...
I dag offentliggjorde Spotlight Group sin delårsrapport för det fjärde kvartalet 2021.
Syncro Group publicerade idag den 16 februari 2022 koncernens delårsrapport för fjärde kvartalet 202...
Taaleri reported Q4 EBIT of EUR 14.7m, coming -8% and +1% versus Refinitiv consensus and Nordea, res...
Redeye returns with a more detailed note on the Q4 report following the conference call.
Tjänsteföretaget Coor är en högintressant aktie i osäkra tider, bedömer Analysguiden.
Inga överraskningar Oncozenge presenterade igår sin rapport för det fjärde kvartalet.
OliveCept-aktiviteter gav effkter i Q4 Omsättningen för Q4 uppgick till 10,6 mkr och 14,8 mkr för 20...
Q-linea's announcement regarding the commercial validation study together with the launch partner Th...
Redeye lowers its forecasts and Base Case following a Q4 report with softer ARR growth than expected...
Redeye comments on Safeture's Q4 report, which showed continued recurring revenue growth above the c...
Redeye sees a mixed Q4 report where the ARPC growth is back in solid territory.
